Alnylam Pharmaceuticals (ALNY) PT Lowered to $125 at BMO Capital; Onpattro U.S. Approval Lacks Benefit From Cardiac Data

BMO Capital analyst Do Kim lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $125.00 (from $127.00) while maintaining an Outperform rating saying the Onpattro U.S. approval lacks benefit from cardiac data.

"We believe the label's lack of cardiac data will pressure the shares in the near term, with unlikely relief from the Tafamidis ESC presentation on August 27," Kim said. "We expect a better setup after ESC and ahead of interim Givosiran data in September 2018."

You May Also Be Interested In

• MarineMax (HZO) PT Lowered to $35 at Stifel
• Tyler Tech (TYL) PT Raised to $500 at Oppenheimer
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen